Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
SHH: 600329.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Lei Wang
- Employees
- 4,619
- Headquarters
- Tianjin, China
- IPO year
- 2001
- Market cap
- CN¥24.0B
- Website
- https://www.zhongxinp.com
Loading 600329…
Loading profile data…Frequently asked questions about 600329
What does Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) do?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sa...
Where does 600329.SS trade?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) trades on the Shanghai Stock Exchange.
What sector is 600329.SS in?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited?
Lei Wang is the chief executive officer of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS).
Where is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited headquartered?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is headquartered in China.
Does 600329.SS pay a dividend?
Yes — Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) paid a trailing twelve-month dividend of CNY 3.73 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 600329.SS go public?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) completed its initial public offering in 2001.